Success Metrics

Clinical Success Rate

90.9%

Based on 10 completed trials

Completion Rate

91%(10/11)

Active Trials

0(0%)

Results Posted

40%(4 trials)

Terminated

1(9%)

Phase Distribution

Ph phase_1

Ph phase_2

Ph phase_4

Ph phase_3

73%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Phase 1Safety & dosage

1(9.1%)

Phase 2Efficacy & side effects

1(9.1%)

Phase 3Large-scale testing

8(72.7%)

Phase 4Post-market surveillance

1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(10)

Terminated(1)

Detailed Status

Completed10

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

90.9%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (9.1%)

Phase 21 (9.1%)

Phase 38 (72.7%)

Phase 41 (9.1%)

Trials by Status

terminated19%

completed1091%

Recent Activity

0 active trials

Showing 5 of 11

completedphase_3

A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

NCT00110435

completedphase_3

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

NCT00132717

completedphase_3

Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)

NCT00090168

completedphase_4

Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)

NCT00442897

completedphase_3

A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)

NCT00462748

View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials

NCT00110435Phase 3

A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

Completed

NCT00132717Phase 3

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

Completed

NCT00090168Phase 3

Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)

Completed

NCT00442897Phase 4

Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)

Completed

NCT00462748Phase 3

A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)

Completed

NCT00496730Phase 3

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

Completed

NCT00276458Phase 3

To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)

Completed

NCT00092690Phase 3

MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)

Completed

NCT00990808Phase 1

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Completed

NCT00977288Phase 2

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Completed

NCT00664469Phase 3

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY